NINDS Clinical Trial Networks (Other Transactions)

NINDS Clinical Trial Networks use Other Transaction Authority to fund the institute's major trial networks through Research Opportunity Announcements. The active networks are NeuroNEXT for exploratory clinical trials and biomarker studies, StrokeNet STEP for endovascular therapy, and URGenT for gene-based therapies for ultra-rare neurological diseases. The funding vehicle is OT2, with a two-stage process and a rolling cadence. The eligibility profile is broad for U.S. institutions and companies, with universities, nonprofits, research organisations, and for-profit firms allowed and individuals excluded. The current opportunities page reports six active ROAs across the three networks. This route is best for teams that can operate in a networked, multi-site trial model and move cleanly through the staged review and activation process that other transaction awards require. The subject matter is narrow and explicit: clinical trials, biomarker work, gene therapy, and stroke thrombectomy appear in the current sector framing, which keeps the fit close to neurological disease infrastructure rather than open-ended discovery research.

Each grant below is a distinct funding opportunity with its own eligibility, scope, and deliverables.